Core Viewpoint - Anteris Technologies Global Corp. has successfully closed a public offering of 40 million shares at a price of $5.75 per share, alongside a private placement of 15.65 million shares to Medtronic, raising approximately $320 million in total gross proceeds [1][2][3]. Group 1: Offering Details - The public offering included the full exercise of underwriters' options to purchase additional shares, with shares sold at $5.75 each [1]. - The private placement involved the sale of shares to Medtronic plc at the same price of $5.75 per share [2]. - The gross proceeds from both the Offering and the Private Placement are approximately $320 million before deducting fees and expenses [3]. Group 2: Use of Proceeds - The net proceeds from the Offering and Private Placement will support the next stage of growth, including the DurAVR® Transcatheter Heart Valve global pivotal trial for severe aortic stenosis patients [5]. - Funds will also be allocated to expand manufacturing capabilities and support ongoing research and development for v2vmedtech, inc., with remaining amounts designated for working capital and general corporate purposes [5]. Group 3: Financial Management - Barclays, Wells Fargo Securities, and Cantor acted as joint book-running managers for the Offering, while Wells Fargo Securities served as the sole placement agent for the private placement [4]. - The Offering was conducted under a shelf registration statement filed with the SEC, which was declared effective on January 8, 2026 [6].

Annual Meeting December 2025 For personal use only NASDAQ: AVR | ASX: AVR Disclaimer Forward-Looking Statements This presentation (including oral commentary that accompanies this presentation) contains forward-looking statements, including statements related to our business, products and clinical trials and studies. Any statements about our expectations, beliefs, plans, predictions, forecasts, objectives, assumptions, or future events or performance are not historical facts and may be forward-looking. In so ...